Search clinical trials for: Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]

Total 2078 results

Taichung Veterans General Hospital
Merck Sharp & Dohme LLC

Terminated

Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation

Liver Transplant Infection | Kidney Transplant Infection | Chronic Hepatitis c

Taiwan
University of Maryland, Baltimore
Merck Sharp & Dohme LLC; Cairo University

Withdrawn

Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4 (CLEAR-C4)

Hepatitis C Virus Infection, Response to Therapy of

Egypt
University of Illinois at Chicago
Merck Sharp & Dohme LLC

Active, not recruiting

Zepatier in Patients With Substance Use

Hepatitis C | Hiv | Substance Use Disorders | Coinfection, HIV

United States
Oregon Health and Science University

Completed

Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care

Substance Abuse, Intravenous | Hepatitis C | Substance Use Disorders

United States
Azienda Ospedaliera Universitaria Policlinico Paolo...

Completed

Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients (EGG-18)

Chronic HCV Hepatitis

Italy
University of Dundee

Completed

A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study (ADVANCE)

Hepatitis C

United Kingdom
University of Pennsylvania
Merck Sharp & Dohme LLC

Completed

Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C (HD)

Hepatitis C | Hemodialysis | Nosocomial Infection

United States
Fundacion Clinic per a la Recerca Biomédica

Unknown

Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients (EARLY-HEP-C)

Hepatitis C | HIV

Spain
Merck Sharp & Dohme LLC

Completed

An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062) (C-EDGE CO-STAR)

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)

Chronic Hepatitis C Virus
Institute Of Cardiology & Internal Diseases, Kazakhstan
Merck Sharp & Dohme LLC; Synergy Research Group

Unknown

Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b

Metabolic Syndrome | Fibrosis, Liver | Cirrhoses, Liver | Chronic Hepatitis C Genotype 1B

Kazakhstan
Merck Sharp & Dohme LLC

Completed

An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)

Chronic Hepatitis C
Fundacion Clinic per a la Recerca Biomédica

Withdrawn

Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients. (EGRADICATE)

Liver Transplantation | Hepatitis C
King Fahad Medical City

Completed

Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4 (ELEGANT-4)

Hepatitis C, Chronic

Saudi Arabia
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)

Hepatitis C
Institut de Médecine et d'Epidémiologie Appliquée...
Merck Sharp & Dohme LLC; Institut National de la Santé Et de la Recherche Médicale...

Completed

Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4 (SAHIV)

HIV | Acute Hepatitis C

France
National Cheng-Kung University Hospital
Merck Sharp & Dohme LLC

Completed

Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan

Drug Interaction Potentiation

Taiwan
San Francisco Veterans Affairs Medical Center
Merck Sharp & Dohme LLC

Unknown

Hepatitis C (HCV) Cure and Kidney Health

Hepatitis C

United States
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)

Hepatitis C
University of California, Los Angeles
Merck Sharp & Dohme LLC

Withdrawn

A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk (HEART-C)

Hepatitis C

United States
Kirby Institute

Terminated

Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs (DARLO-C)

Hepatitis C

Australia
University of Maryland, Baltimore

Completed

HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant

Renal Insufficiency, Chronic | Hepatitis C | Disorder of Transplanted Kidney

United States
Kaohsiung Medical University Chung-Ho Memorial...

Completed

8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis

Hepatitis C, Chronic

Taiwan
Norte Study Group
Merck Sharp & Dohme LLC

Unknown

Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C

Chronic Hepatitis C

Japan
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)

Hepatitis C Virus (HCV) Infection

France
Radboud University Medical Center

Completed

Bioequivalence Study of Crushed Elbasvir/Grazoprevir Compared to the Whole Tablet (CRUSADE-2)

Hepatitis C | Deglutition Disorders

Netherlands
Fundacion SEIMC-GESIDA

Withdrawn

A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A (C-RESCUE)

HCV

Spain
Massachusetts General Hospital

Withdrawn

Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant

Hepatitis C | Renal Failure Chronic

United States
Massachusetts General Hospital
Merck Sharp & Dohme LLC

Completed

Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant

Renal Failure

United States
Albert Einstein Healthcare Network
Merck Sharp & Dohme LLC; Davita Clinical Research

Withdrawn

A Prospective Cohort Study to Improve HCV Care in Dialysis Patients (MATCH-D)

Hepatitis C
AstraZeneca

Completed

AZD5069 Neutrophil Function Study

Chemokine Receptor 2 (CXCR2) Antagonist

United Kingdom
University of Pennsylvania
Merck Sharp & Dohme LLC

Completed

Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV) (USHER)

Heart Failure

United States
Merck Sharp & Dohme LLC

Withdrawn

Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)

Hepatitis C
University of Zurich

Completed

Swiss HCVree Trial (HCVree)

Hepatitis C | HIV

Switzerland
Sprout Pharmaceuticals, Inc

Completed

Flibanserin Versus Placebo in Premenopausal Women With HSDD

Sexual Dysfunctions, Psychological

Austria, Belgium, Czech Republic, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom
Tobira Therapeutics, Inc.

Completed

A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients

HIV-1 Infection
National Taiwan University Hospital
Merck Sharp & Dohme LLC

Completed

EBR/GZR for HCV-1b Patients Receiving Hemodialysis

Hepatitis C

Taiwan
King's College Hospital NHS Trust
Merck Sharp & Dohme LLC; Hepatitis C Trust

Terminated

ATTIC - Access To Treat in the Community (ATTIC)

Hepatitis C, Chronic

United Kingdom
ANRS, Emerging Infectious Diseases

Completed

Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir

Hepatitis C
University of Pennsylvania
Merck Sharp & Dohme LLC

Completed

Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients (THINKER)

End Stage Renal Disease

United States
Dallas VA Medical Center
Merck Sharp & Dohme LLC

Terminated

Impact of Hepatitis C Therapy and Bone Health (HCV)

Hepatitis C | Human Immunodeficiency Virus

United States
Johns Hopkins University
Merck Sharp & Dohme LLC

Completed

Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients (EXPANDER-1)

Hepatitis C | End-Stage Renal Disease

United States
Eisai Co., Ltd.

Completed

A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease

Coronary Artery Disease

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-40411813 in Male and Female Elderly Patients

Healthy

Belgium
Galapagos NV

Completed

Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy Subjects

Healthy

United Kingdom
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes

Type 2 Diabetes

China
Oxford Cannabinoid Technologies Holdings PLC
Simbec-Orion Group

Completed

Single Ascending Oral Dose Study to Investigate the Effects of OCT461201 in Healthy Volunteers

Healthy

United Kingdom
Galapagos NV

Completed

A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

Cystic Fibrosis

Spain, United Kingdom, United States, Netherlands, Belgium, Serbia
GlaxoSmithKline

Terminated

An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184

Systemic Lupus Erythematosus

Estonia, Germany, South Africa, Peru, Sweden, France, Korea, Republic of, Hong Kong, Spain, Romania, Czechia, Argentina, Chile, Hungary, Greece, Poland
CymaBay Therapeutics, Inc.

Completed

Study to Evaluate the Effects of MBX-8025 in Patients With HoFH

Homozygous Familial Hypercholesterolemia

Canada, France, Netherlands, Norway

3

Subscribe